Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company is headquartered in San Diego, California.
| Revenue (TTM) | $1.80B |
| Gross Profit (TTM) | $1.40B |
| EBITDA | $1.14B |
| Operating Margin | 59.80% |
| Return on Equity | 216.40% |
| Return on Assets | 22.40% |
| Revenue/Share (TTM) | $15.45 |
| Book Value | $-0.48 |
| Price-to-Book | 97.15 |
| Price-to-Sales (TTM) | 6.53 |
| EV/Revenue | 9.53 |
| EV/EBITDA | 22.08 |
| Quarterly Earnings Growth (YoY) | 40.60% |
| Quarterly Revenue Growth (YoY) | 39.20% |
| Shares Outstanding | $113.50M |
| Float | $112.69M |
| % Insiders | 1.08% |
| % Institutions | 114.13% |
Volatility is currently expanding
HALO's Q3 earnings & revenues beat estimates, driven by higher royalties and product sales. The company raises its 2026 outlook, yet shares fall in after-hours.
Halozyme lifts its 2026 outlook after a 44% royalty surge, as ENHANZE expansion, Hypercon trials and a Merck patent dispute draw investors' focus.
SAN DIEGO, Nov. 6, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today confirmed that the Company expects zero to minimal royalty revenue impact based on its analysis of the final rule for the Medicare Drug Price Negotiation Program ("Program") issued by the U.S. Centers for Medicare & Medicaid Services ("CMS") on November 5th, 2026. "Based on our analysis of CMS's final rule and the statutory framework established under the One Big Beautiful Bill Act ("OBBBA"), Halozyme projects zero to minimal impact to its royalty revenues through at least 2035.
Approval extends RYBREVANT FASPRO's well-established, dual-targeted benefit beyond lung cancer SAN DIEGO, Nov. 6, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) (Halozyme) today announced that Johnson & Johnson was granted accelerated approval from the U.S. Food and Drug Administration (FDA) for RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj), which is co-formulated with ENHANZE®, as a single agent for the treatment of adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease has progressed on or after platinum-based chemotherapy and an anti-PD-(L)1 antibody. The indication does not include patients with oropharyngeal squamous cell carcinoma that is HPV-associated.
Halozyme Therapeutics NASDAQ: HALO raised its full-year 2026 guidance after reporting record third-quarter revenue and royalties, driven by growth in established partner products and contributions from newer subcutaneous drug launches.
Total Revenue Increased 39% YOY to $493 million Royalty Revenue Increased 44% YOY to $341 million Raising 2026 Financial Guidance Ranges: Total Revenue of $1.860 - $1.925 billion, YOY Growth of 33% - 38% Royalty Revenue of $1.235 - $1.255 billion, YOY Growth of 42% - 45% Adjusted EBITDA of $1.240 - $1.290 billion, YOY Growth of 89% - 96% 1 Non-GAAP Diluted EPS of $8.75 - $9.05, YOY Growth of 111% - 118% 1 Expanded ENHANZE ® Collaboration Agreements with Three Current Partners Three ENHANZE ® Programs Advanced into Phase 1 Clinical Development SAN DIEGO, Nov. 5, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today reported its financial and operating results for the third quarter ended September 30, 2026, and provided an update on its recent corporate activities. "Halozyme delivered another exceptional quarter, with total revenue increasing 39% and royalty revenue growing 44% year-over-year to record levels," said Dr. Helen Torley, President and Chief Executive Officer.
Evaluate the expected performance of Halozyme Therapeutics (HALO) for the quarter ended September 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Halozyme is poised for a Q3 earnings beat as strong demand for partnered drugs is likely to boost royalties and drive the top line.
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Halozyme Therapeutics (HALO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on HALO and any ticker you trade — then tracks every position and per-strategy win rate.
